Cargando…
TIAM2 Contributes to Osimertinib Resistance, Cell Motility, and Tumor-Associated Macrophage M2-like Polarization in Lung Adenocarcinoma
Background: Osimertinib-based therapy effectively improves the prognosis of lung adenocarcinoma (LUAD) patients with epidermal growth factor receptor mutations. However, patients will have cancer progression after approximately one year due to the occurrence of drug resistance. Extensive evidence ha...
Autores principales: | Liang, Lu, He, Hua, Jiang, Shiyao, Liu, Yueying, Huang, Jingjing, Sun, Xiaoyan, Li, Yi, Jiang, Yiqun, Cong, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499457/ https://www.ncbi.nlm.nih.gov/pubmed/36142328 http://dx.doi.org/10.3390/ijms231810415 |
Ejemplares similares
-
NCAPG2 Maintains Cancer Stemness and Promotes Erlotinib Resistance in Lung Adenocarcinoma
por: Jiang, Shiyao, et al.
Publicado: (2022) -
KIF20A is associated with clinical prognosis and synergistic effect of gemcitabine combined with ferroptosis inducer in lung adenocarcinoma
por: He, Hua, et al.
Publicado: (2022) -
Novel Circulating Tumour Cell-Related Risk Model Indicates Prognosis and Immune Infiltration in Lung Adenocarcinoma
por: Liang, Lu, et al.
Publicado: (2022) -
Analysis of PANoptosis-Related LncRNA-miRNA-mRNA Network Reveals LncRNA SNHG7 Involved in Chemo-Resistance in Colon Adenocarcinoma
por: Huang, Jingjing, et al.
Publicado: (2022) -
Integrative analysis of T cell motility from multi-channel microscopy data using TIAM
por: Mayya, Viveka, et al.
Publicado: (2015)